MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 ...

How to improve Windows 11 security using Administrator Protection — shielding your PC with a switch buried in its settings

Open the following path: Computer Configuration > Windows Settings > Security Settings > Local Policies > Security Options ...

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial ...

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 ...
Everyday Health on MSN

Expert Q&A: Your Questions About the Cost of ADT for Advanced Prostate Cancer, Answered

Dr. Adam Weiner answers common questions about the costs of androgen deprivation therapy (ADT) for advanced prostate cancer and how to find help paying for it.
StockStory.org on MSN

Why ADT (ADT) Shares Are Plunging Today

What Happened? Shares of security technology and services company ADT (NYSE:ADT) fell 6.2% in the morning session after it ...

ADT (NYSE:ADT) Posts Q3 Sales In Line With Estimates

Security technology and services company ADT (NYSE:ADT) met Wall Streets revenue expectations in Q3 CY2025, with sales up 4.4 ...
Philstar.com

Corpus stumbles late, falls short of Egyptian Open golf crown

For a moment, it looked like Carl Corpus was on the verge of another Asian Development Tour victory. Showing poise and precision under pressure, Corpus mounted a fiery back-nine charge to seize a ...